Detalles de la búsqueda
1.
Measurement of B-domain-deleted ReFacto AF activity with a product-specific standard is affected by choice of reagent and patient-specific factors.
Haemophilia
; 24(4): 675-682, 2018 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-28124445
2.
The adsorption of dabigatran is as efficient as addition of idarucizumab to neutralize the drug in routine coagulation assays.
Int J Lab Hematol
; 40(4): 442-447, 2018 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-29573340
3.
The amplitude of coagulation curves from thrombin time tests allows dysfibrinogenemia caused by the common mutation FGG-Arg301 to be distinguished from hypofibrinogenemia.
Int J Lab Hematol
; 39(3): 301-307, 2017 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-28318107
4.
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders.
J Thromb Haemost
; 13(11): 2087-92, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26347330
Resultados
1 -
4
de 4
1
Próxima >
>>